Progyny Inc. Stock Grades | PGNY
This article provides a stock overview for Progyny Inc. (PGNY), including its stock grades, analyst ratings, key financial metrics such as market value, EPS, and P/E ratio, and a brief company description. It also lists peer companies and data providers.
PGNY Initiates Coverage On Wells Fargo -- Rating Set to Overweig
Wells Fargo has initiated coverage on Progyny (PGNY) with an Overweight rating and a price target of $37.00. GuruFocus indicates PGNY is 14.5% undervalued with a GF Value™ of $29.11 and boasts a high GF Score™ of 96/100, reflecting strong financial strength, growth, valuation, and momentum. Despite some insider selling and mixed guru activity, the overall outlook suggests PGNY is a compelling investment opportunity.
Liquidity Mapping Around (PGNY) Price Events
This article analyzes Progyny Inc. (NASDAQ: PGNY) using AI models, highlighting a weak near-term sentiment despite long-term strength. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis, including support and resistance levels for various time horizons.
Officer at Progyny (PGNY) plans about $102K stock sale
Progyny, Inc. (PGNY) Officer Allison C. Swartz plans to sell 3,903 common shares with an aggregate market value of $101,868.30, scheduled for an approximate sale date of September 23, 2026. The SEC Form 144 filing indicates Fidelity Brokerage Services LLC as the broker and notes 76,726,798 Progyny shares outstanding. The filing also details upcoming restricted stock vesting events for Swartz on August 28, September 3, and September 4, 2026.
Progyny (NASDAQ:PGNY): A Quality Investing Watchlist Candidate
Progyny (NASDAQ:PGNY) is identified as a strong candidate for a quality investor's watchlist based on its robust financial health, profitability, and growth metrics. The company demonstrates steady revenue and EBIT growth, high returns on invested capital, and a debt-free balance sheet. While its valuation is moderate on a forward basis and future earnings growth is expected, potential risks include a recent slowdown in revenue growth and concentration in the U.S. market.
Progyny (PGNY) CPO reports 819-share tax withholding
Progyny, Inc.'s Chief Product Officer, Geoffrey Clapp, had 819 shares of common stock withheld on September 17, 2026, to cover tax obligations from vested restricted stock units. This tax-withholding disposition was priced at $27.38 per share, leaving Clapp with 59,009 directly held shares of Progyny common stock. The transaction was not conducted under a Rule 10b5-1 trading plan.
Progyny (NASDAQ: PGNY) director sells 11,500 shares after exercising options
Progyny (NASDAQ: PGNY) director Kevin K. Gordon reported exercising stock options for 22,000 shares at $13.00 per share and subsequently selling 11,500 shares at a corrected weighted average price of $27.1181 per share. The Form 4/A filing amends a previous report to correct a clerical error in the sale price. This transaction involved shares being withheld to cover exercise costs and tax liabilities.
Progyny Director Gordon Kevin K Executes 22,000 Stock Options at $13 Each (NASDAQ: PGNY)
Progyny, Inc. director Gordon Kevin K exercised 22,000 stock options at $13 per share on September 10, 2026. On the same day, he also forfeited 10,500 shares at $27.24 each and sold 11,500 shares at $27.94 each. These transactions adjusted his direct shareholdings to 6,792 shares and derivative securities to 22,000 shares.
Options Movement At Progyny: KEVIN GORDON Exercises Worth $325K
KEVIN GORDON, a Board Member at Progyny (NASDAQ: PGNY), exercised stock options worth $325,600 for 22,000 shares, as reported in a recent SEC filing. The article details Progyny's financial performance, including a 5.3% revenue growth, a 25.48% gross margin, and a low debt-to-equity ratio, while highlighting potential undervaluation based on P/E, P/S, and EV/EBITDA ratios. It also explains the significance of insider trading and the various transaction codes.
Progyny director Kevin Gordon sells $321,358 in company stock
Progyny director Kevin Gordon sold 11,500 shares of company stock worth $321,358 on September 10, 2026, after exercising options to acquire 22,000 shares. This transaction follows a period of significant stock growth and strong Q2 2026 financial results, which included exceeding analyst expectations for earnings and revenue. Analysts maintain a positive outlook for Progyny, with Citizens raising its price target due to strategic initiatives like the CalPERS partnership and a new pooled risk offering.
Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2
This article analyzes the Q2 earnings season for health insurance providers, highlighting Progyny (NASDAQ:PGNY) as having the weakest guidance update despite a revenue beat. It contrasts Progyny's performance with other companies like CVS Health, Molina Healthcare, Alignment Healthcare, and Clover Health, detailing their Q2 results. The article also touches upon broader industry challenges and tailwinds, including regulatory scrutiny, AI's impact, and changing market concerns from AI to geopolitics.
Progyny, Inc. (NASDAQ: PGNY) Insider Swartz Allison Forfeits 1,307 Shares at $26.29-$26.61 Range
Progyny, Inc. insider Swartz Allison forfeited 1,307 shares in two separate transactions on September 3 and September 4, 2026. The shares were priced between $26.29 and $26.61, and these forfeitures were classified as tax-related withholdings. Following these transactions, Swartz Allison's remaining ownership in Progyny stands at 79,719 shares.
Progyny at Wells Fargo healthcare conference: growth runway stays wide By Investing.com
Progyny presented a mixed but constructive business outlook at the Wells Fargo 21st Annual Healthcare Conference, highlighting seasonal utilization softness but significant growth opportunities. The company, a leading fertility benefits administrator, plans to expand into new women's health offerings and tap into a broader market, including smaller employers through its Progyny Select program. Despite recent guidance adjustments, Progyny emphasizes strong demand, cash generation, and share repurchases, with management confident in long-term growth driven by core fertility services and new product lines.
Progyny CFO Mark S. Livingston Reports Share Withholding on RSU Vesting
Progyny's CFO, Mark S. Livingston, reported a share withholding transaction related to the vesting of restricted stock units (RSUs). On September 4, 2026, 479 shares were retained to cover tax obligations, each valued at $26.61. Following this, Livingston directly holds 72,453 shares of Progyny common stock.
Avoiding Lag: Real-Time Signals in (PGNY) Movement
Progyny Inc. (NASDAQ: PGNY) is showing strong near-term sentiment that could shift to neutrality mid-term and a positive long-term bias. The stock is currently testing resistance, with specific trading strategies generated by AI models for various risk profiles, including long, breakout, and short positions based on real-time signals.
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
Progyny, Inc. announced that its Chief Financial Officer, Mark Livingston, will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. The presentation will be available via live audiocast and replay on Progyny's investor relations website. Progyny is a global leader in women's health and family building solutions.
Progyny, Inc. to Present at the Wells Fargo Healthcare Conference
Progyny, Inc. announced that its CFO, Mark Livingston, will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, at 11:00 a.m. ET. A live audiocast and replay will be available on the company's investor relations website. Progyny is a global leader in women's health and family building solutions, recognized for its comprehensive and inclusive benefits.
Progyny stock price target maintained at $31 by Citizens on new offering
Citizens has reiterated a Market Outperform rating and a $31.00 price target for Progyny (NASDAQ:PGNY) shares, citing the company's new pooled risk, fixed premium offering, Select, which is expected to expand its addressable market significantly. Despite a recent post-earnings decline due to investor concerns about a summer slowdown, Progyny reported strong Q2 2026 results, exceeding revenue and EPS expectations. Citizens believes Select could generate over $130M in margin-accretive revenue by 2030, even though it's not yet factored into their financial model.
Progyny (NASDAQ:PGNY): An Affordable Growth Stock With Strong Earnings and Reasonable Valuation
Progyny (NASDAQ:PGNY) is presented as an affordable growth stock, combining strong earnings growth with reasonable valuation multiples and solid financial health. The article highlights its impressive EPS growth, attractive valuation ratios compared to its industry, and strong health and profitability ratings, including a debt-free balance sheet. While acknowledging potential risks like slowing revenue growth and a low gross margin, the analysis suggests PGNY offers a reasonable price for its projected earnings expansion.
JPMorgan Chase & Co. Boosts Progyny (NASDAQ:PGNY) Price Target to $30.00
JPMorgan Chase & Co. raised its price target for Progyny (NASDAQ:PGNY) to $30.00 from $27.00, maintaining a "neutral" rating and suggesting a 17.23% upside. This follows Progyny's strong quarterly earnings, beating expectations with $0.55 EPS on $350.51 million in revenue, and the authorization of a $200 million share repurchase program. The company currently holds a "Moderate Buy" consensus rating among analysts, with an average target price of $33.91.
Tocqueville Asset Management L.P. Takes Position in Progyny, Inc. $PGNY
Tocqueville Asset Management L.P. has acquired a new position in Progyny, Inc. (NASDAQ:PGNY), purchasing 84,000 shares valued at approximately $2.42 million. This comes as Progyny exceeded quarterly earnings and revenue expectations, reporting $0.55 EPS against a $0.33 consensus and $350.51 million in revenue, up 5.3% year over year. The company also authorized a $200 million share repurchase program and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $34.36.
Danske Bank A S Purchases Shares of 528,717 Progyny, Inc. $PGNY
Danske Bank A S recently acquired a new position in Progyny, Inc. (NASDAQ:PGNY), purchasing 528,717 shares valued at approximately $15.24 million in the second quarter. Other institutional investors also adjusted their holdings in Progyny, which has seen some insider selling of shares. Wall Street analysts currently rate Progyny as a "Moderate Buy" with an average price target of $34.36, and the company recently announced a $200 million share repurchase program.
PGNY Initiated Coverage by Wells Fargo -- Rating Overweight Anno
Wells Fargo has initiated coverage on Progyny (PGNY) with an "Overweight" rating and a price target of $37.00. The stock is currently trading at $26.22, showing an 8.8% undervaluation according to GuruFocus's GF Value™, and holds a strong GF Score™ of 93/100, driven by excellent growth and valuation metrics. While guru ownership shows mixed activity and there has been some insider selling, the overall outlook suggests a promising investment opportunity for PGNY in the healthcare sector.
Wells Fargo Initiates Progyny(PGNY.US) With Buy Rating, Announces Target Price $37
Wells Fargo has initiated coverage on Progyny (PGNY.US) with a "Buy" rating. The firm has set a price target of $37 for the company's shares. This indicates a positive outlook from Wells Fargo regarding Progyny's future stock performance.
Bank of America Corp DE Grows Stake in Progyny, Inc. $PGNY
Bank of America Corp DE significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 75.3% in the first quarter, now owning 1.19 million shares valued at $20.2 million. This comes as Progyny reported strong quarterly earnings, beating analyst expectations, and authorized a $200 million share repurchase program. Despite some insider selling, analysts maintain a "Moderate Buy" rating with a consensus target price of $34.10.
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook
Progyny (NASDAQ: PGNY) anticipates a rebound in fertility-treatment utilization after a summer slowdown, with September appointment trends returning to earlier levels. The company's full-year outlook is de-risked by early renewal commitments and strong new-client acquisition, targeting at least 1 million new covered lives. Progyny also sees expanding growth opportunities, including replacement business, health-plan partnerships, and new offerings like Progyny Select, which has increased its estimated addressable market to 155 million lives.
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook
Progyny's CEO, Pete Anevski, announced that the company anticipates a rebound in member engagement and utilization after a more significant summer slowdown. Early renewal commitments and new client acquisitions have bolstered management's confidence in the company's financial outlook for the remainder of the year. Progyny also reported stronger early new-business commitments and an expansion of its client base across numerous industries, de-risking its renewal rates for the upcoming year.
Discipline and Rules-Based Execution in PGNY Response
This article provides an AI-generated analysis for Progyny Inc. (NASDAQ: PGNY), highlighting a weak near and mid-term sentiment that could challenge a positive long-term outlook. It details specific trading strategies for various risk profiles, including long and short positions with defined entry points, targets, and stop losses. The analysis also includes multi-timeframe signal analysis, emphasizing support and resistance levels.
Royal Bank of Canada Has $3.71 Million Stock Position in Progyny, Inc. $PGNY
Royal Bank of Canada significantly increased its stake in Progyny, Inc. (NASDAQ:PGNY) by 98% in the first quarter, now owning 218,434 shares valued at $3.71 million. Other institutional investors also adjusted their positions, and 94.93% of Progyny stock is held by institutional investors and hedge funds. Despite some insider selling, analysts generally have a "Moderate Buy" rating with an average target price of $34.10, and the company has authorized a $200 million share repurchase program, suggesting management views the stock as undervalued.
Truist Financial Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $36
Truist Financial has reiterated its Buy rating on Progyny (PGNY.US) and set a target price of $36. This indicates the firm's continued confidence in the company's stock performance.
Truist Adjusts Price Target on Progyny to $36 From $33, Maintains Buy Rating
Truist Securities has increased its price target for Progyny (PGNY) to $36 from $33, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's valuation.
Truist Adjusts Price Target on Progyny to $36 From $33, Maintains Buy Rating
Truist has increased its price target for Progyny (PGNY) from $33 to $36, while reiterating a Buy rating on the stock. This adjustment follows Progyny's Q2 2026 earnings report, where the company exceeded revenue estimates. Progyny, a benefit management company specializing in fertility and family building solutions, also provided optimistic guidance for its Q3 2026 revenue and adjusted EPS.
PGNY Maintains Rating by Barclays -- Price Target Lowered to $30
Barclays has maintained an Equal-Weight rating on Progyny (PGNY) but lowered its price target to $30 from $34. Despite this, Progyny is considered undervalued by GuruFocus with a GF Value™ of $28.56 against its current price of $26.55, and boasts a strong GF Score™ of 91/100, indicating robust financial health and growth potential. However, a mixed sentiment from institutional investors and significant insider selling suggest caution for potential investors.
Sei Investments Co. Decreases Stake in Progyny, Inc. $PGNY
Sei Investments Co. reduced its stake in Progyny, Inc. by 46.9% in the first quarter, selling over 71,000 shares and retaining a holding valued at $1.37 million. Despite this reduction, institutional investors collectively own 94.93% of Progyny, which has a consensus "Moderate Buy" rating and an average price target of $34.20 from analysts. The company also announced a $200 million stock repurchase program, while insiders have sold a significant number of shares recently.
Progyny Drops 5.4% Amid Sector-Wide Selling
Progyny, Inc. experienced a 5.4% decline, closing at $26.34, as part of a sector-wide selloff affecting healthcare plan providers. The drop, accompanied by similar losses in peer companies like ALHC and MRDH, suggests broader investor repositioning rather than company-specific news. Investors are advised to monitor whether this sector weakness persists or if individual company fundamentals begin to differentiate performance.
Progyny, Inc. $PGNY Shares Sold by Janus Henderson Group PLC
Janus Henderson Group PLC significantly reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 84.1% in the first quarter, selling over 200,000 shares. Despite this, institutional investors collectively hold 94.93% of the company's stock, and analyst sentiment remains positive with a "Moderate Buy" consensus and a $34.20 price target. Progyny also announced a $200 million share repurchase program, indicating management believes the stock is undervalued.
Why Progyny (PGNY) Shares Are Sliding Today
Progyny's shares dropped by 4.5% after the company issued a weaker-than-expected forecast for the upcoming quarter and lowered its full-year revenue and EBITDA guidance, despite beating second-quarter earnings estimates. This disappointing outlook overshadowed strong Q2 results and previous analyst upgrades, leading to a significant sell-off. The stock is currently trading 12.4% below its 52-week high, and investors who bought 5 years ago would have seen a significant loss.
Quantinno Capital Management LP Grows Position in Progyny, Inc. $PGNY
Quantinno Capital Management LP significantly increased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 382.6
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
Progyny, Inc. (Nasdaq: PGNY) announced that CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 3:30 p.m. ET. A live audiocast and replays will be available on the company's investor relations website. Progyny is a global leader in women's health and family building solutions, recognized for its comprehensive and inclusive benefit solutions.
Progyny, Inc. 2026: Revenue $350.51M, EPS $0.34— 10-Q Summary
Progyny, Inc. reported strong second-quarter 2026 results, with revenue reaching $350.51 million and diluted EPS of $0.34, showcasing modest top-line growth and significant profitability improvement year-over-year. The company expanded its client base to over 600, covering approximately 7.2 million lives, and saw improved gross margins due to care management efficiencies.
Progyny, Inc. Stock 12‑Month Price Target Cut to $33.82, Implies 12% Upside
Progyny, Inc.'s average stock price target has been reduced to $33.82 from $34 by 11 analysts, with individual forecasts ranging from $27 to $40 per share. This updated target suggests a potential 12% upside based on the Aug. 6 closing price. The consensus rating for Progyny remains a "Buy" among the 11 covering analysts.
Progyny Posts Record Q2 Results, Expands Client Base
Progyny reported record second-quarter 2026 results with revenue of $350.5 million, up 5.3% year-over-year, and a 13% increase in gross profit to $89.3 million, despite losing a large client. The company also saw net income rise to $28.1 million and adjusted EBITDA to $62.1 million, driven by efficiency gains. Progyny expanded its client base to 604 customers and repurchased 1.2 million shares, reinforcing its position in the employer-sponsored women's health benefits market, leading TipRanks' AI Analyst, Spark, to rate the stock as "Outperform."
Why Progyny Stock Plunged, Then Gradually Recovered Today
Progyny's stock initially dropped by 6% after its second-quarter earnings report, despite sales rising 5% and adjusted earnings per share increasing by 15%, both exceeding Wall Street expectations. The market reacted negatively to management's conservative Q3 revenue growth guidance of 7% to 11%. However, the company's solid Q2 performance, including expanding gross profit margins and the introduction of its new "Progyny Select" offering for smaller employers, suggests a positive long-term outlook, leading to a gradual recovery in the stock price.
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
Progyny, Inc. announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 3:30 p.m. ET. The presentation will be accessible via a live audiocast and replay on Progyny’s investor relations website. Progyny is a leading company in women's health and family building solutions, recognized for its comprehensive approach to improving health outcomes and reducing healthcare costs.
Progyny CEO’s Aug. 11 Boston session will have a live audiocast
Progyny, Inc. (Nasdaq: PGNY) announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA, on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be accessible via the Events and Presentations section of Progyny’s investor relations website. The presentation will offer insights into Progyny's role as a leader in women’s health and family building solutions.
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
Progyny, Inc. announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 3:30 p.m. ET. The presentation will be audiocast live and available for replay on Progyny's investor relations website. Progyny is a global leader in women's health and family building solutions.
Progyny, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PGNY) 2026-08-07
Progyny, Inc. has published its Q2 2026 earnings call presentation. The company reported EPS of $0.55, beating estimates by $0.03, and revenue of $350.51 million, surpassing expectations by $1.86 million, representing a 5.30% year-over-year increase. This article provides access to the slide deck presented during the earnings call.
Progyny Inc (PGNY) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA Amid Strategic ...
Progyny Inc (PGNY) reported record revenue, gross profit, and adjusted EBITDA for Q2 2026, with revenue increasing 5.3% year-over-year. The company provided full-year 2026 guidance, projecting revenue between $1.36 billion and $1.385 billion, and reaffirmed strong selling season momentum and client retention. Despite a slight downward adjustment in Q3 guidance due to summer seasonality, Progyny continues to generate strong cash flow and execute significant share repurchases.
Progyny, Inc. Announces Second Quarter 2026 Results
Progyny, Inc. reported strong second-quarter 2026 financial results, with record quarterly revenue of $350.5 million, gross profit of $89.3 million, and Adjusted EBITDA of $62.1 million. The company's CEO, Pete Anevski, highlighted robust member engagement and strong momentum in the selling season, while CFO Mark Livingston emphasized gross margin expansion and effective conversion of Adjusted EBITDA to operating cash flow. Progyny also provided financial guidance for the third quarter and full year 2026, projecting continued growth in revenue and earnings, and announced the repurchase of over 2 million shares under its current authorization.
Progyny Q2 2026 earnings: Margin expansion lifts profit faster than revenue
Progyny (Nasdaq: PGNY) reported Q2 2026 revenue of $350.5 million, a 5.3% year-over-year increase, and diluted EPS of $0.34, significantly up from $0.19 in Q2 2025. The company's profit growth outpaced revenue growth due to gross-margin expansion and lower stock-based compensation, despite a decline in quarterly operating cash flow. Management provided guidance for Q3 and full-year 2026, anticipating a seasonal slowdown in Q3 but strong selling-season momentum.
